JAMES HEALY
CIK 1245624 · last filed 2026-06-12
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$557.20M
Companies
21
Total Filings
151
Lifetime Open-Market Net
$113.76M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| BIOA | Director | 2,227,124 | $21.92 | $48.82M | $12.00M | 3 | 2026-06-12 |
| RAPP | Director | 39,661 | $41.96 | $1.66M | $10.58M | 4 | 2026-06-10 |
| SPTX | Director | 2,731,538 | $19.90 | $54.36M | $0 | 1 | 2026-05-04 |
| Y-mAbs Therapeutics, Inc. (YMAB) Delisted | Director | 2,250,961 | $8.61 | $19.38M | $10.52M | 10 | 2025-07-02 |
| NTRA | Director | 1,596,540 | $252.22 | $402.68M | -$22.23M | 33 | 2025-04-29 |
| BOLT | Director | 115,222 | $4.02 | $463.2K | $9.00M | 5 | 2024-06-14 |
| Karuna Therapeutics, Inc. (KRTX) Delisted | Director | 0 | $329.83 | $0 | $44.62M | 16 | 2024-03-18 |
| AVBP | Director | 1,252,308 | $29.98 | $37.54M | $8.00M | 1 | 2024-01-31 |
| CinCor Pharma, Inc. (CINC) Delisted | Director | 6,103,360 | $29.06 | $177.36M | $20.38M | 3 | 2022-08-15 |
| CHRS | Director | 70,086 | $1.44 | $100.9K | -$22.15M | 19 | 2022-02-11 |
| Iterum Therapeutics plc (ITRM) Delisted | Director | 115,511 | $0.03 | $3.5K | $6.50M | 5 | 2020-01-23 |
| Entasis Therapeutics Holdings Inc. (ETTX) Delisted | 10%+ Owner | 842,454 | $2.19 | $1.84M | $25.33M | 1 | 2018-10-02 |
| EDGE | Director | 142,636 | $49.76 | $7.10M | $8.90M | 4 | 2017-06-21 |
| AMRN | Director | 320,579 | $13.95 | $4.47M | -$47.71M | 13 | 2016-07-13 |
| HYPERION THERAPEUTICS INC (HPTX) Delisted | Director | 0 | — | — | -$3.55M | 3 | 2015-05-08 |
| ALIMERA SCIENCES INC (ALIM) Delisted | 10%+ Owner | 169,753 | $5.54 | $940.4K | $0 | 1 | 2014-09-15 |
| MARINUS PHARMACEUTICALS, INC. (MRNS) Delisted | 10%+ Owner | 7,000 | $0.55 | $3.9K | $54.05M | 1 | 2014-08-07 |
| Anthera Pharmaceuticals Inc (ANTH) Delisted | Director | 10,719 | — | — | -$474.0K | 8 | 2013-05-20 |
| HUMANIGEN, INC (KBIO) Delisted | Director | 3,173 | — | — | $0 | 2 | 2013-05-02 |
| Paratek Pharmaceuticals, Inc. (NOVC) Delisted | Director | 2,178,437 | — | — | $0 | 3 | 2008-03-31 |
| COTHERIX INC (CTRX) Delisted | Director | 0 | — | — | $0 | 2 | 2007-01-10 |
Recent Filings · Page 2 of 16
151 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2024-09-27 | BIOA | Mixed | +2,304,901 | $12.00M | EDGAR |
| 2024-07-30 | NTRA | Grant (A) | +177 | $0 | EDGAR |
| 2024-07-03 | RAPP | Buy (P) | +44,032 | $1.08M | EDGAR |
| 2024-07-02 | NTRA | Grant (A) | +2,964 | $0 | EDGAR |
| 2024-06-14 | BOLT | Grant (A) | — | $0 | EDGAR |
| 2024-06-13 | Y-mAbs Therapeutics, Inc. (YMAB) Delisted | Grant (A) | +3,495 | $0 | EDGAR |
| 2024-06-10 | RAPP | Mixed | +1,951,562 | $9.50M | EDGAR |
| 2024-04-30 | NTRA | Grant (A) | +210 | $0 | EDGAR |
| 2024-03-18 | Karuna Therapeutics, Inc. (KRTX) Delisted | Disp (D) | −1,414,639 | -$466.83M | EDGAR |
| 2024-01-31 | AVBP | Mixed | +1,696,752 | $8.00M | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.